Gilead Sciences GILD Yescarta — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's yescarta — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's yescarta — total revenues?
- Gilead Sciences (GILD) reported yescarta — total revenues of $332M in Q1 2026.
- How has Gilead Sciences's yescarta — total revenues changed year-over-year?
- Gilead Sciences's yescarta — total revenues decreased by 14.0% year-over-year, from $386M to $332M.
- What is the long-term trend for Gilead Sciences's yescarta — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's yescarta — total revenues has grown at a 21.1% compound annual growth rate (CAGR), from $695M to $1.5B.
- What does yescarta — total revenues mean?
- The total revenue generated from the sale of the company's specific CAR-T cell therapy product.
- How do you interpret yescarta — total revenues?
- An increase indicates growing market penetration and successful clinical adoption of the therapy, while a decrease may signal increased competition, pricing pressure, or shifts in treatment guidelines.
- How does yescarta — total revenues compare across companies?
- Comparable to revenue metrics for specialized oncology or cell therapy product lines at other major biopharmaceutical companies, often benchmarked against market share in specific cancer indications.